17 results
Thumbnail

D1.244 - Clinical heterogeneity of pediatric atopic dermatitis: latent class analysis

Thumbnail

D1.241 - Clinical and Immunological Phenotypes of Alopecia Areata in Children with Atopic Dermatitis

Thumbnail

D1.236 - The role of tissue resident memory cells in immunodermatological disorders: A Systematic Review

Thumbnail

D1.237 - Mental Health and Neurodevelopmental Comorbidities in Pediatric Atopic Dermatitis: A Retrospective Study and Literature-Based Perspective

Thumbnail

D1.245 - The role of advanced glycation end products as facilitating factors in the pathogenesis of atopic dermatitis in pediatric patients

Thumbnail

D1.246 - Characterization of Unmet Need for Targeted Precision Medication in Atopic Dermatitis Due to Inadequate Response or Adverse Reactions to Dupilumab

Thumbnail

D2.480 - Features of the molecular sensitization profile in children with autism spectrum disorder

Thumbnail

D2.485 - Comprehensive Understanding of the Characteristics of Pediatric Pollen Allergy Patients

Thumbnail

D2.486 - Levels of house dust mite in dust settlements are associated with risk for allergic rhinitis in children

Thumbnail

D2.479 - The bullous pemphigoid in a baby

Thumbnail

D2.481 - Severe obstructive syndrome in children with bronchopulmonary malformations

Thumbnail

D2.488 - Functional confirmation of exercise-induced bronchoconstriction in children: A three-year retrospective study

Thumbnail

D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region

Thumbnail

D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor

Thumbnail

D3.155 - Th2–Th17 immune shift following dupilumab therapy

Thumbnail

D3.160 - Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry

Thumbnail

D3.164 - Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma